The Guardian
· collected 2026-09-17 · by Denis Campbell and Anna Bawden
Ministers and drug makers AstraZeneca and Daiichi Sankyo reached an agreement on pricing for Enhertu, allowing approximately 1,000 women in England with HER2-low advanced breast cancer to receive the life-extending drug starting Thursday. The National Institute for Health and Care Excellence (Nice) previously rejected the drug due to its cost but now recommends routine NHS use after negotiations led to a new pricing agreement. Clinical trials show Enhertu almost doubles median progression-free survival compared to traditional chemotherapy, from 5.1 months to 9.9 months, with overall survival increasing by 6.6 months on average.
Written by the local model on 2026-09-17,
using this article's own text rather than the other coverage of the
same event (that is the story summary below).
Story summary
In a significant development, thousands of women in England with incurable HER2-low advanced breast cancer will gain access to Enhertu through the National Health Service (NHS). After successful negotiations over its cost, about 1,000 patients annually will be eligible for this life-extending drug starting from Thursday. Clinical trials have shown that Enhertu nearly doubles median progression-free survival compared to standard chemotherapy—from 5.1 months to 9.9 months—and increases overall survival by an average of 6.6 months. The National Institute for Health and Care Excellence (Nice) has recommended the treatment for routine use following changes made to its framework under the UK-US pharmaceutical partnership, enabling more patients to benefit from cutting-edge treatments. Claire Rowney, CEO of Breast Cancer Now, emphasized that this decision is a momentous achievement that will provide "precious time" with loved ones for those affected by breast cancer.
Written for “Breast Cancer Drug Access England” on 2026-09-17,
grounded in this article and the 0 other(s) covering the same event.
Thousands of women in England with incurable breast cancer will get access to a life-extending drug on the NHS after negotiations over its cost proved successful.
asserted
negotiations → get → cost
About 1,000 women a year with HER2-low advanced breast cancer will be able to obtain Enhertu from Thursday after ministers and the drug’s makers struck a deal on its price.
asserted
ministers → obtain → price
About one in seven of the 60,000 new cases of breast cancer diagnosed every year in the UK are HER2-positive.
asserted
seven → diagnose → UK
Clinical trials have shown that Enhertu almost doubled median progression-free survival compared with normal chemotherapy, from 5.1 months to 9.9 months.
asserted
Enhertu → show → months
Median overall survival among people who used it was 23.4 months, compared with 16.8 months among those not on it – a 6.6-month gain.
asserted
who → use → it
“This is a momentous day for thousands of people who will now have access to a drug that will give them the opportunity to gain precious time with loved ones”, said Claire Rowney, the chief executive of Breast Cancer Now.
asserted
Rowney → have → Cancer
The National Institute for Health and Care Excellence (Nice) announced on Thursday that about 1,000 patients a year in England will be eligible to receive the treatment from the NHS after it recommended it for routine use.
asserted
it → announce → use
Nice, which advises the NHS on whether treatments represent value for money, had previously rejected Enhertu, in July 2024, as too expensive to justify, despite its proven effectiveness.
asserted
treatments → advise → effectiveness
Rowney hailed “this milestone victory”, which follows two years of determined campaigning by the charity, cancer specialists and women with that form of breast cancer.
asserted
which → hail → cancer
The drug has been available since December 2023 in Scotland, which is one of 27 European countries that provide it to patients.
asserted
that → provide → patients
Labour ministers, including ex-health secretary Wes Streeting, have been working behind the scenes for some time to add England to that list by brokering a deal on cost.
asserted
ministers → include → cost
Their efforts were hampered by the drugmakers’ refusal to lower their price.
asserted
efforts → hamper → price
Nice’s U-turn follows recent renewed negotiations between it, NHS England and Enhertu’s two makers, the pharmaceutical firms AstraZeneca and Daiichi Sankyo.
asserted
turn → follow → it
They resulted in what Nice called “a commercial solution” that means the drug is now available in England for the first time.
asserted
drug → result → time
The freedom that Nice gained in April to recommend that the NHS can spend up to £35,000 a year on a patient’s treatment, up from a previous maximum of £30,000, proved crucial.
asserted
NHS → gain → 30,000
It has agreed to pay more for Enhertu than it was previously prepared to do.
asserted
it → agree → Enhertu
But it is unclear if the drug’s two makers reciprocated by reducing the amount they had been seeking.
uncertain
they → reciprocate → amount
“This is hugely positive news for women with secondary breast cancer who will now be offered this life-extending treatment on the NHS,” said Dr Anne Rigg, a consultant medical oncologist who is also NHS England’s national speciality adviser for chemotherapy.
asserted
who → offer → chemotherapy
Dr Catherine Elliott, Cancer Research UK’s director of research, said: “Enhertu is a targeted treatment that delivers chemotherapy directly to cancer cells.
asserted
that → say → cells
“Clinical trial results show that, for people with HER2-low advanced breast cancer whose disease has progressed following treatment, it can help them live longer and delay their cancer from getting worse compared with standard chemotherapy.”
asserted
them → show → chemotherapy
Ministers in Wales and Northern Ireland are likely to implement Nice’s recommendation and make it available there too.
asserted
it → implement → recommendation
Yvette Cooper, the health secretary, said: “Enhertu can be life-changing and this recommendation means NHS patients will finally be able to benefit from it.
“
asserted
patients → say → it
It is a tribute to the campaigners and charities who never stopped pressing for this, and it follows the changes this government has made to the Nice framework as part of the UK-US pharmaceutical partnership so more people can benefit from cutting-edge treatments.”
asserted
people → stop → treatments
The Aporia
